The Living Rare, Living Stronger Patient and Family Forum, originally set for May 14–16 in Cleveland, Ohio, has been postponed until July 18–20 because of the coronavirus disease COVID-19 pandemic. The event’s sponsor, the National Organization for Rare Disorders (NORD), said it will still take place at the…
News
Idiopathic pulmonary fibrosis (IPF) is associated with a substantial economic burden in the United States, especially for patients who require hospitalization, intensive care, or a lung transplant, a study based on registry data reported. Annual average costs for 3.9 days in a hospital by patients in this study was…
Ofev (nintedanib) limits the decline in lung function in people with idiopathic pulmonary fibrosis (IPF), regardless of the degree of impairment in gas exchange in their lungs, a study suggests. According to the researchers in the study, “these data support the use of [Ofev] in patients with IPF…
Surgeons were able to successfully transplant a donor’s left lung into the right side of a patient’s lung cavity, according to a case report of a patient with idiopathic pulmonary fibrosis (IPF) — suggesting that this technique can be used under challenging situations in which donor lungs are not…
Even with the coronavirus pandemic ravaging Europe and much of the world, patient advocate Lucia Monaco, PhD, of Italy remains confident that the Paris-based nonprofit she chairs will see the approval of 1,000 new rare disease therapies by 2027. That group, the International Rare Diseases Research Consortium (IRDiRC) —…
Stimulating the aryl hydrocarbon receptor (AhR), found across the immune system, via a naturally produced chemical protected mice from induced pulmonary fibrosis (PF) and increased their survival, a study showed. These findings support further research to determine if AhR might…
A clinical trial in the U.K. is recruiting people with idiopathic pulmonary fibrosis (IPF) to test Trevi Therapeutics’ nalbuphine extended release tablets to treat chronic cough, the company announced. Nalbuphine extended release (ER) acts in two ways: the small molecule blocks the mu opioid receptor, while it…
Patients with interstitial lung disease (ILD), including pulmonary fibrosis (PF), have an increased risk of coronary heart disease and heart attack, compared to those without these lung conditions, a recent study suggests. Clinicians should take these findings into account, and screen patients with ILDs, especially those 60–69 years…
Hepion Pharmaceuticals‘ CRV431 has a similar, or even greater effect in reducing markers of idiopathic pulmonary fibrosis (IPF) in lung tissue, compared with standard-of-care IPF treatment, the company reported. The therapy had positive results in lung tissue from an IPF patient, according to Hepion. CRV431 is a…
The U.S. Food and Drug Administration (FDA) and Bellerophon Therapeutics agreed on the design of Bellerophon’s Phase 3 trial to test INOpulse — inhaled nitric oxide — in people with pulmonary fibrosis (PF) who are at risk for pulmonary hypertension (PH), the company said. INOpulse is a device that…
